Cysteine-Engineered Antibody Conjugates for Homogeneous Drug Attachment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional methods for attaching drug moieties to antibodies result in heterogeneous mixtures and stability issues due to the introduction of cysteine residues, leading to protein aggregation, misfolding, and reduced serum stability of antibody-drug conjugates.
Innovation Solution
Cysteine-engineered antibodies and Fc fusion proteins with specific cysteine amino acid substitutions or insertions at defined positions, allowing for targeted conjugation of heterologous moieties such as drugs, toxins, or radionuclides, enhancing stability and maintaining antigen binding specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If cysteine residues are introduced into antibodies by genetic engineering to form covalent attachments to ligands, then conjugation capability is improved, but protein aggregation and misfolding occur leading to reduced stability
Solution Approach 1:
The patent applies local quality by introducing cysteine residues at specific, predetermined positions within the antibody molecule (such as positions 241, 243, 251, 253, 258, 264, 269, 271, 272, 274, 280, 281, 285, 288, 291, 293, 294, 296, 301, 307, 309, 311, 318, 329, 340, 341, 345, 357, 385, 386, 387, 401, 402, 411, 417, 433, 435, or 439 according to EU indexing). This localized introduction of reactive cysteines at controlled positions enables conjugation capability while avoiding random cysteine introduction that would cause aggregation and misfolding, thus resolving the contradiction between conjugation versatility and protein stability.
2Productivity
If cysteine residues are introduced into antibodies to enable drug conjugation, then conjugation efficiency is improved, but serum stability is reduced due to proteolytic degradation and clearance
Solution Approach 1:
The patent introduces cysteine residues at specific positions within the Fc domain of the antibody (such as positions 241, 243, 251, 253, 258, 264, 269, 271, 272, 274, 280, 281, 285, 288, 291, 293, 294, 296, 301, 307, 309, 311, 318, 329, 340, 341, 345, 357, 385, 386, 387, 401, 402, 411, 417, 433, 435, or 439 according to EU indexing). This localized approach enables efficient drug conjugation at predetermined sites while maintaining the overall structural integrity and serum stability of the antibody, resolving the contradiction between conjugation efficiency and serum stability.
3Ease of manufacture
If conventional methods are used to attach drug moieties to antibodies through lysine residues, then conjugation is achieved, but heterogeneous mixtures are produced reducing manufacturing precision
Solution Approach 1:
The patent replaces conventional lysine-based conjugation with cysteine-based conjugation at specific predetermined positions (such as positions 241, 243, 251, 253, 258, 264, 269, 271, 272, 274, 280, 281, 285, 288, 291, 293, 294, 296, 301, 307, 309, 311, 318, 329, 340, 341, 345, 357, 385, 386, 387, 401, 402, 411, 417, 433, 435, or 439 according to EU indexing). This localized cysteine introduction creates defined conjugation sites that produce homogeneous antibody-drug conjugates, resolving the contradiction between manufacturing simplicity and conjugate homogeneity.
Solution Approach 2:
The patent segments the antibody structure by identifying specific cysteine introduction positions within the Fc domain (such as positions 241, 243, 251, 253, 258, 264, 269, 271, 272, 274, 280, 281, 285, 288, 291, 293, 294, 296, 301, 307, 309, 311, 318, 329, 340, 341, 345, 357, 385, 386, 387, 401, 402, 411, 417, 433, 435, or 439 according to EU indexing). This segmentation creates discrete, controlled conjugation sites that prevent random drug attachment, thereby producing homogeneous conjugates while maintaining ease of manufacture.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The cysteine-engineered conjugate compounds demonstrate improved serum stability and conjugation efficiency, maintaining therapeutic efficacy and diagnostic utility while minimizing off-target toxicity.
Implementation Method 1
Cysteine residues have been introduced into proteins by genetic engineering techniques to form covalent attachments to ligands
Data Source
AI summary
This disclosure provides conjugate compounds comprising antibodies and fragments thereof engineered with one or more reactive cysteine residues and more specifically to conjugate compounds with therapeutic or diagnostic applications. The conjugate compounds comprise cysteine-engineered antibodies or fragments thereof conjugated, for example, with chemotherapeutic drugs, toxins, and detection labels such as radionuclides or fluorophores. The disclosure also provides methods of using the disclosed conjugate compounds for in vitro, in situ, ex vivo, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.